Septal surgery is a common type of otolaryngology-head and neck surgery, and it is often performed in combination with other proc edures. Complications ofseptal surgery include bleeding, hematoma, inf ection, abscessformation, and perforation. The most common methods of preventing these complications are the use of nasal packing, septa l splints, and quilting sutures as a means of approximating the septalflap s. In this article, we describe our study of an alternate method: fi brin glue. We used fi brin glue as the sole method ofapproximating flap s on 100 consecutive septal surgery patients. Our results indicate that the use offibrin glue is effective, rapid, comfortable, and inexpen sive.
Introduction
Septal operations are common in otolaryngology-head and neck surgery, both alone and in combination with other procedures. Common ancillary procedures include inferior turbinoplasty, endoscopic sinus surgery, and rhinoplasty.
Complications of septal surgery include bleedin g, hematoma, infection , abscess form ation, and perforation. Rhinologic surgeons use a variety of technique s to prevent these potential complic ations. The most common are the use of nasal packing (with various materials left in place for variou s amounts of time), septal splints, and quilting sutures to approximate the septal flaps. In this article, we describe our study of fibrin glue as an alternative to these three method s.
Patients and methods
We used fibrin glue as the sole means of approximating septal flaps in 100 consecutive patients who underwent septal surgery alone or in combination with other procedures. Near the end of each procedure, we placed a thin layer of fibrin glue between the septal flaps, and we made certain that all surfaces were covered and enough glue was used to extend to the incision. The flaps were then pressed togeth er for 30 seconds with an osteotome or other flat instrument. No packing or suture was used.
Results
Among the 100 patients, there were no hematomas, infections, or perforation s. One patient developed bleeding at the incision site several hours postoperatively and required the temporary placement of Gelfoam. No other complic ations were observed.
Discussion
Little research has been done on the true effectiveness of septopla sty. Jang et al found a disparity in mucocili ary transport between the convex and concave sides of the septum.' They demon strated that the concave side has a longer saccharin clearance time, a more significant loss of cilia, fewer seromucous glands, and more inflammat ory cells than does the convex side. Thu s, mucociliary transport is impaired on the concave side. I Rhinologic surgeons generally focus on the convex side as a cause of airway obstruction or as a predisposing factor in sinusitis. Although the latter point is widely believed, it is unproven scientifically. Pirila and Tikanto recently demonstrated that septoplasty resulted in an increase in nasal airflow and in the cross-sectional area on the convex side.! Interestingly, they found that these features deteriorated on the concave side following septoplasty.
Prevention of complications is important in such a common procedure . Nasal packing, septal splints, and quiltin g sutures work well in this regard, although each has its disadvantages . inhal ed bronchodilators are needed more often than usual , or if more than the maximum number of inhalations of short-actingbronchodilator freatment prescribedfor a24-hour periodareneeded. • Patients receiving SINGULAIR shoul d beinstructednot to decrease the dose or stoptaking any other anti-asthma medications unless instructedby a physician. • Patients who haveexacerbationsof asthmaafter exerciseshould beinstructed to continueto usetheir usual regimen of inhal edI)-agonists asprophylaxis unl ess otherwiseinstructed bytheir physician. All patients should have available for rescuea short-acting inhaled I)-agonist. • Pati ents wi th known aspirin sensi tivityshoul d beadvised to continueavoidance of aspirin or non-steroidal anti-inflammatoryagentswhiletaking SINGULAIR.
Chewable Tablets
• Phenylketonurics: Phenylketonuric patientsshouldbeinformedthat the4-mgand5-mg chewabletablets contain phenylal anine (a component of aspartame), 0.674 and0.842 mgper4-mg and 5-mg chewable tablet, respectively. Drug Interactions: SINGULAIR has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma with no apparent increase in adverse reactions. In drug-interaction studies, the recom mendedclini cal dose of mont elukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 meg), terfenadine, digoxin, and warfari n. Al thoughadditional specific interaction studieswere not performed, SINGULAIRwas used concomitantly with a wide range of commonly prescribed drugs in clinical studieswithout evidence of clinical adverse interactions.These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatoryagents, benzodiazepi nes, and decongestant s. Phenobarbital , which induces hepatic metaboli sm, decreased theAUC of rnontetukast approximatel y 40% following a single 10-mg doseof montelukast. Nodosage adjustment for SINGULAIRis recommended. It is reasonableto employ appropriate clinical monitoringwhen potent cytochrome P450 enzym e inducers, suchasphenobarbital or rilampin, areco-administered with SINGULAIR. Carcinogenesis, Mutagenesis, Impairment of Fertility: Noevidence of tumorigenicity was seen in eithera 2-yearcarcinogenicitystudy in Sprague-Dawley ratsatoral gavage doses upto 200mglkg/day (estimated exposure was approximately 90 times the area underthe plasma concentration versus time curve (AUG) for adults and children at the maximum recommendeddai ly oral dose) or in a 92-week carcinogenicity study in miceat oral gavagedoses up to 100 mglkg/day(estimated exposurewasapproximately30times theAUC for adul ts andchildren at the maximum recommended dail y oral dose). Montelukast demonstrated no evidence of mutagenic or clastogenic activity in the following assays: the microbiai mutagenesis assay, the V-79 mammalian cell mutagenesis assay, the alkaline elution assay in rat hepatocytes, the chromosomal aberration assay in Chinese hamsterovary cells, and in the in vivo mouse bonemarrow chromosomal aberration assay. Infertility studies infemalerats, montel ukast produced reductionsinfertility andfecundi ty indi cesat an oral dose of 200mglkg (est imated exposure was approximately 70fimes the AUC for adults at the maximum recommendeddaily oral dose). Noeffects on female fertility or fecundity were observed atan oral dose of 100 mglkg (estimated exposure was approximately 20 times the AU C for adul ts at the maximum recomm endeddaily oral dose). Montelukast hadno effects on fertility in male rats at oral doses up to 800 mglkg (estimated exposure was approxi mately 160 times the AUC for adults at the maximum recommended daily oral dose). Pregnancy, Teratogenic Effects Pregnancy Category8: Noteratogeni city wasobserved in ratsat oraldoses upto 400 mglkg/day (estimated exposure was approximately 100 times theAUC for adults at the maximumrecommended daily oral dose) and inrabbit sat oral doses upto 300mglkglday (estimat edexposure wasapproximately 11 0times theAUC for adults at the maximum recommendeddaily oral dose). Montelukast crosses the pl acenta followi ng oral dosing in rats and rabbits. Thereare, however, no adequateand well-controlled studies in preg nant women. Because animal reproduction studies arenot al ways predictive of human response, SINGULAIR should be usedduring preg nancyonly if clearly needed. Merck & Co., Inc. maintains a registry to moni tor the pregnancy outcomes of women exposed to SINGULAIR while pregnant. Heal thcare providers are encouraged to report any prenatal exposure to SINGULAIRby calling the Pregnancy Registry at (800) 986-8999. Nursing Mot her s: Studies in rats have shown that montelukast is excreted in mi lk. It is not known if montelukast is excreted in humanmi lk. Becausemany drugs are excreted in humanmilk, caution should be exer cised when SINGULAIRis given to a nursing mother.
Pediatric Use: Safetyand efficacy ofSINGULAIR' (montelukast sodium)havebeenestablishedinadequate and well-eontrolled studies inpediatric patients withasthma 6 to14yearsof age. Safety and efficacy profiles inthis age group are similar tothoseseen inadul ts. (See Clinical St udiesinthePrescribingInformationandADVERSE REACTIONS.) The efficacy of SINGULAIRfor thetreatment of seasonal allergic rhinitis in pediatric patients 2 to 14 years of ageis supported by ext rapolation from thedemonstrated effi cacy in patients 15 years of age and older with seasonal allergic rhinitis aswell as theassumption thatthe disease course , pathophysiology and the drug's effect are substantially similar among these popuianons. Thesafety of SINGULAIR4-mgchewabl etablet sin pediatric patients 2 to5yearsof agewi thasthma has been demonstratedbyadequateandwell-controlled dat a(seeADVERSEREACTIONS). EfficacyofSI NGULAIR inthi s age group is extrapolated fromfhedemonstratedeff icacyinpatients 6yearsof ageand olderwi thasthmaand is based on si mi lar pharmacokinetic dat a, aswell astheassumption that thedisease course, pathophysiology and thedrug'seffect are substantiall y similar among these populations. Efficacyinthisagegroup is supported byexploratory efficacyassessmentsfromalarge, well-controlledsafety stuoyconductedinpat ients 2to5years of age. The safety of SINGULAIR 4-mg and 5-mgchewable tabl ets in pediatric patients aged 2 to 14 years with seasonal allergic rhinitis is supported by data fromstudiesconductedin pediatric pati ents aged 2 to 14 years with asthma. A safety studyin pediatric patients 2 to 14years of age with seasonal allergic rhinitis demonstrated a similar safety profile (see ADVERSEREACTIONS). Thesafetyandeffecti veness inpediat ricpatientsbelowtheage of 2yearshavenot beenestablished. Long-term trials evaluating theeffec t of chronic administration of SINGULAIR on linear growth in pediatric patients have not been conducted. Geriatric Use: Ofthetotalnumberof subj ectsinclinical studies ofmontelukast, 3.5% were 65yearsof age and overand 0.4% were 75years of age and over . No overall differences in safety oreffectiveness wereobserved bet ween these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elder ly and younger patients, but greater sensi tivityof some older individuais cannot beruled out.
ADVERSE REACTIONS
Adults andAdolescents 15 Years of AgeandOlder withAsthma: SINGULAIR has been evaluat ed for safety in appr oxim at ely 2600 adult and adolescent patients 15 years of age and older in clinical trial s. In pl acebo-controlledclinical trials, thefoll owing adverseexperiences reported wi th SINGULAIRoccurred in~1% of patients and at an incidence greater than that in pati ents treated wi th placebo, regardless of causality assessment: SINGULAIR 10 mglday (n=1955) vs pl acebo (n=1180), respectivel y. Bod y as a whole: asthenia/fatigue(1.8% vs t .2%); fever (1.5% vs 0.9%); pain, abdomi nal (2.9% vs 2.5%); trauma (1.0% vs 0.8%). Digestive system disorders:dyspepsia (2.1% vs 1.1%); gastroenterit is, infectious(1.5%vs 0.5%); pain, dental (1.7% vs 1.0%). Nervoussystem/psychiatric: dizziness (1. 9% vs 1.4%); headache (18.4% vs 18.1 %). Respiratorysystem disorders:congestion,nasal (1.6%vs1. 3%);cough(2.7%vs2.4%); influenza (4.2%vs3.9%). Skin/ skin appendages disorder. ' rash (1.6% vs 1. 2%). Labo ratoryadverse experiences (number of patients tested ISI NGULAIRand pl acebo, respectively]: ALTand AST, 1935 AST, , 1170 pyuria,192 4, 1159) : ALT increased (2.1% vs 2.0%); ASTincreased (1.6%vs1.2%); pyuria (1. 0%vs 0.9%). Thefrequency of lesscom mo nadver seeventswas comparablebetweenSINGULAIRand placebo. Cumulatively, 569 patients weretreat edwithSINGULAIRforatleast6 months, 480for oneyear, and49for two years in clinical trials. With prolonged treatment, the adverseexperience profiledidnot significantly change. Pediatric Patients 6 to 14 Years of Age wit h Ast hma: SINGULAIR has been evaluat edfor safety in 321 pediatric patients 6 to 14 years of age. Cumuiati vely, 169 pediatric patients were treatedwith SINGULAIRfor at least 6 months, and 121 for oneyear or longer in clinical trials. The safety profile of SINGULAJR in the 8-week, double-bl ind, pediatric efficacy trial was generall y similar to theadul t safety profile. In pediatric patients6 to 14 years of age receiving SINGULAIR, thefollowing events occurred with afrequency;,2%and more frequentiy than in pediatric patients who recei ved placebo, regardless of causality assessment: pharyngitis, influenza, fever , sinusitis, nausea, diarrhea, dyspepsia, otitis, virai infection, and laryngitis. The frequency of less common adverse events was comparabl e between SINGULAIR and pl acebo. Wi th prolong ed treatment, theadverse exper ience profiledidnot significantly change. Pediatric Patients 2 to5 YearsofAge wi thAsthma: SINGULAIRhas been evaluatedtor safety in573 pediatric pati ents2to5yearsof age in si ngle andmultipledosestudies. Cumulatively, 426pediatric patients2to5years were treated wi th SINGULAIRfor at least 3 months, 230 for6 months or longer, and63patients for oneyear or longer inclinica l trials. SINGULAIR4 mgadministered once daily atbedtimewas generally \'Iell tol erated in cli nical trials. Inpediatric patients2 to5 years of age receiving SINGULAIR,thefollowingeventsoccurredwi th a frequency~% and more frequently than in pediatric patients whoreceived placebo, regardless of causality assessment: fever , cough, abdomi nal pain, diarrhea, headache, rhinorrhea, si nusitis, otitis, influenza, rash, ear pain, gastroenteritis, eczema, urticaria, varicella, pneumonia, der matitis, and c on j u nc t i v~i s . Adults andAdolescents 15Years of Age and Older wi th Seasonal Allergic Rhinitis: SINGULAIRhas been evaluat ed for safety in 2199 adul t and adolescent pati ents 15 years of age and older in clinical triais. SINGULAIR administered once daily in the morning or in the evening was generally well tol erated with a safety prof ilesimi lar to that of placebo. In placebo-controll ed clinical triais, thefollowing event was reported with SINGULAIRwith a frequency of~1 % and at an incidencegreaterthanplacebo, regardless of causality assessment: upper respiratory infection, 1.9% of patients receiving SINGULAIR vs. 1.5% of patients receivingpl acebo. In a 4-week, placebo-controlled clinical study, the safety profile was consistent wi th that observed in2-week studies. The incidence of somnolence was similar to that of placeboin allstudies. Pediatric Patients 2 to 14 YearsofAgewithSeasonal Allergic Rhinitis: SINGULAIRhasbeenevaluated in280 pedi atric patients 2 to 14 years of age in a 2-week, multicenter , double-blind, placebo-controlled, parallel-group, safety study. SINGULAIRadmi nistered once daily in the evening was gener all y well tolerated with a safety profilesimilar to that of placebo. In this study, the following events occurred with a frequency ;,2% and at an incidence greaterthan placebo, regardless of causality assessment:headache, otitis media, pharyn gitis, and upper respiratory infection. Post-Marketing Experience: The following additional adverse reactions have been reported in post-marketinguse: hypersensitivity reactions (including anaphylaxis,angioedema, pruritus, urticaria, and very rarely, hepatic eosi nophilic infiltration); dream abnormalities and hallucinations, drowsiness, irritability, agitation inclUding aggressive behavior, restlessness, insomnia, and very rarely seizures; nausea, vomi ting, dyspepsia, diarrhea, and very rarely pancreatitis; arthralgia, myalgiainclUding muscle cramps; increased bleeding tendency, bruising; palpitations; and edema. In rare cases, patients with asthma on therapy wi th SINGULAIR may present wi th systemic eosinophi lia, sometimes presentingwithclinical features of vasculitisconsistent wi th Churg-Strausssyndrome, acondition which is often treated wi th systemic corticosteroid therapy. These events usually, but not always, havebeen associ ated with the reduction of oral corticosteroid therapy. Physicians should be alert to eosinophilia, vasculiticrash, worseningpulmonary symptoms, cardiaccomplications, and/or neuropathypresentingintheir patients. Acausal association betweenSINGULAIRand these underlying conditions has not been established (see PRECAUTIONS, Eosinophilic Conditions). DOSAGE ANO AOMINISTRATION GeneralInformat ion: SI NGULAIRshouldbetakenoncedaily. For asthma,the doseshouldbetakenintheevening. Forseasonal all ergic rhini tis, thetimeof admini stration may beindividualizedtosui t patient needs. Patients wi thbothasthma and seasonal allergic rhinitisshould take only onetablet dailyinthe evening. Rhinologists consider packing a time-honored and wellaccepted procedure, largely because of its ease and stellar effectiveness. Nevertheless, nasal pack s are uncomfortable while they are in place and they cause pain and bleeding when they are removed. Ogretmenoglu et al recently reported that bilateral nasal packing leads to a significant decrease in oxygen saturation lev els and heart rates in healthy young patients.' Toxic shock syndrome following nasal packing has been reported many times , first by Thomas et al in 1982. 4 Septal splints can be used in lieu of packing to stabilize the septal flaps . However, in' a pro spective, randomized study, Malki et al found that patients who received splints experienced significantly more pain than did those who did not .'
Septal suturing has also been proposed as an alternative to packing, despite concerns about its inabi lity to effectively stabilize the septal cartilage .s? Stability was recently studied by Lemmens and Lemkens in a seri es of 226 consecutive patients who underwent septal suturing only ." In that serie s, only one patient experienced a recurrence of the deviation. Nevertheless, a notable disadvantage of suturing is the amount of time it requires.
The use of fibrin glue as an alternative to these three methods has several advantages. For example, while suturing requires 5 to 10 min utes to complete, even by expert hands, the placement of fibrin glue takes less than 60 seconds (including the compression time) . Furthermore, at our institution, the cost of operating room time is $4 1 per min ute, while fibrin glue costs $100/6 ml.
The use of fibrin glue in septoplasty has been reported only twice prev iously. In 1979, Wu llstein described the first cases of septoplasty that were performed with the assistance of "biological adhesives."? In 1987 , Hayward and Mackay reported on 30 patients who had been treated with fibrin glue.'?
Fibrin glue is readily available in at least two forms. Under the trade name Tisseel, it has been commercially available in the United States for approximately 3 years, and it has been used in Europe for decades . Fibrin glue can also be compounded extemporaneously by mixing cryoprecipitate and thrombin. The latter formulation , which we used in our study , can be easily obtained and is less expensive than the commercial product.
We conclude that fibrin glue is a rapid and reliable method of approximating septal flaps and preventing complications associated with septoplasty .
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